Abstract:Protein kinases play pivotal roles in various biological functions, influencing cell differentiation, promoting survival, and regulating the cell cycle. The disruption of protein kinase activity is intricately linked to pathways in tumor development. This manuscript explores the transformative impact of protein kinase inhibitors on cancer therapy, particularly their efficacy in cases driven by targeted mutations. Focusing on key tyrosine kinase inhibitors (TKIs) like Bcr-Abl, Epidermal Growth Factor Receptor (EGFR), and Vascular Endothelial Growth Factor Receptor (VEGFR), it targets critical kinase families in cancer progression. Clinical trial details of these TKIs offer insights into their therapeutic potentials. Learning from FDA-approved kinase inhibitors, the review dissects trends in kinase drug development since imatinib's paradigm-shifting approval in 2001. TKIs have evolved into pivotal drugs, extending beyond oncology. Ongoing clinical trials explore novel kinase targets, revealing the vast potential within the human kinome. The manuscript provides a detailed analysis of advancements until 2022, discussing the roles of specific oncogenic protein kinases in cancer development and carcinogenesis. Our exploration on PubMed for relevant and significant TKIs undergoing pre-FDA approval phase III clinical trials enriches the discussion with valuable findings. While kinase inhibitors exhibit lower toxicity than traditional chemotherapy in cancer treatment, challenges like resistance and side effects emphasize the necessity of understanding resistance mechanisms, prompting the development of novel inhibitors like osimertinib targeting specific mutant proteins. The review advocates thorough research on effective combination therapies, highlighting the future development of more selective RTKIs to optimize patient-specific cancer treatment and reduce adverse events.

Advances in Small-Molecule Inhibitors of Protein Tyrosine Kinases

Review on the Research Development of Small Molecular Protein Tyrosine Kinases Inhibitors

Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy

Small Molecules Targeting Phosphoinositide 3-Kinases

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

The Progress of Tyrosine kinase Inhibitors in Cancer Therapy

Emerging Roles of Targeted Small Molecule Protein-Tyrosine Kinase Inhibitors in Cancer Therapy

Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors As Anticancer Agents

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Advances in the Research of Small Molecule Tyrosine Kinase Inhibitors

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond

Targeting PTPs with small molecule inhibitors in cancer treatment

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020

Structure-Activity Relationship of Substituted Pyrazoline Derivatives as Small Molecule Tyrosine Kinase Inhibitors

FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I

Exploring receptor tyrosine kinases-inhibitors in Cancer treatments

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors

Current Status of Research and Development of New Tyrosine Kinase Inhibitors

Protein-Tyrosine Kinases Inhibitors from Microorganisms